ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Silexion Therapeutics Corporation

Silexion Therapeutics Corporation (SLXN)

2,22
0,07
( 3,26% )
Mis à jour : 15:40:55
Graphique avancé
Rendering Error

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
2,22
Prix Achat
2,16
Prix Vente
2,25
Volume échangé
21 244
2,15 Fourchette du Jour 2,25
1,863 Plage de 52 semaines 36,36
Clôture Veille
2,15
Ouverture
2,15
Dernière Transaction
1
@
2.205
Dernière heure de transaction
15:41:38
Volume moyen (3 m)
4 643 055
Volume financier
US$ 47 360
VWAP
2,2293

SLXN Dernières nouvelles

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology with a focus on KRAS-driven cancers, among the most challenging targets in oncology. In collaboration with Evonik, Silexion...

Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development

Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

Silexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXN

December 11, 2024 -- InvestorsHub NewsWire -- via PESG Research -- The field of precision oncology has witnessed groundbreaking advancements in recent years, and Silexion Therapeutics (NASDAQ:...

Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies...

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Latest preclinical studies reveal significant improvements in stability, efficacy, and KRAS targeting range for next-generation siRNA candidate SIL-204 Silexion Therapeutics Corp. (NASDAQ: SLXN...

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer Silexion Therapeutics Corp...

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the...

Sielox Reports Second Quarter Sales Growth of 82.5% and Significant Improvement in Financial Performance

RUNNEMEDE, N.J., Aug. 15 /PRNewswire-FirstCall/ -- Sielox, Inc. (OTC:SLXN) (BULLETIN BOARD: SLXN) , a developer, designer and distributor of security solution and industrial vision products...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.115.213270142182.112.32991.9221109832.1036807CS
4-0.39-14.94252873562.614.231.9229136892.95542587CS
12-0.372-14.35185185192.5924.231.86346430553.02601841CS
26-33.78-93.83333333333636.361.86342356214.75384594CS
52-33.78-93.83333333333636.361.86342356214.75384594CS
156-33.78-93.83333333333636.361.86342356214.75384594CS
260-33.78-93.83333333333636.361.86342356214.75384594CS

SLXN - Frequently Asked Questions (FAQ)

What is the current Silexion Therapeutics share price?
The current share price of Silexion Therapeutics is US$ 2,22
What is the 1 year trading range for Silexion Therapeutics share price?
Silexion Therapeutics has traded in the range of US$ 1,863 to US$ 36,36 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MEGLMagic Empire Global Limited
US$ 1,14
(102,81%)
60,77M
SPRCSciSparc Ltd
US$ 0,9217
(74,60%)
45,28M
ARBEArbe Robotics Ltd
US$ 4,20
(59,70%)
47,43M
HUBCWHub Cyber Security Ltd
US$ 0,063
(57,50%)
111,08k
KITTNauticus Robotics Inc
US$ 5,86
(54,21%)
22,23M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,086
(-41,81%)
7,39M
GCTKGlucoTrack Inc
US$ 0,173
(-41,02%)
4,98M
LUNALuna Innovations Incorporated
US$ 1,31
(-36,10%)
729,57k
BLRXBioLineRx Ltd
US$ 0,18245
(-33,36%)
9,09M
NITON2OFF Inc
US$ 1,91
(-27,65%)
5,76M
CNSPCNS Pharmaceuticals Inc
US$ 0,1551
(26,10%)
122,47M
MEGLMagic Empire Global Limited
US$ 1,14
(102,81%)
60,77M
ARBEArbe Robotics Ltd
US$ 4,20
(59,70%)
47,43M
SPRCSciSparc Ltd
US$ 0,9217
(74,60%)
45,28M
MBOTMicrobot Medical Inc
US$ 2,89
(35,05%)
28,97M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock